Advances in Ocular Drug Delivery Systems

Michael Andrew Carter [1*], Jennifer Louise Hughes [2], Daniel Robert Bennett [3], Ashley Nicole Thompson [4]
[1] Department of Pharmaceutical Sciences, University of California, San Diego, United States
[2] Center for Nanomedicine, Johns Hopkins University, Baltimore, United States
[3] Division of Drug Delivery Systems, University of Michigan, Ann Arbor, United States
[4] Department of Oncology Nanotherapeutics, MD Anderson Cancer Center, Houston, United States

* Corresponding Author: **Dr. CH Kantlam**

Article Info

ISSN (online): 3107-393X
Volume: 02
Issue: 02
March-April 2025
Received: 23-02-2025
Accepted: 27-03-2025
Published: 21-04-2025
Page No: 16-21

Abstract
Ocular drug delivery remains a formidable challenge in pharmaceutical sciences owing to the unique anatomical and physiological barriers of the eye, including the tear film, corneal epithelium, and blood-retinal barrier, which collectively limit the bioavailability of conventionally administered ophthalmic formulations. The aim of this review is to consolidate current advances in ocular drug delivery systems with emphasis on nanotechnology-based carriers, controlled-release platforms, and emerging therapeutic modalities. Conventional systems such as eye drops, ointments, and suspensions achieve limited precorneal residence and sub-therapeutic drug levels, necessitating the development of sophisticated delivery platforms. Modern strategies encompassing polymeric nanoparticles, liposomes, solid lipid nanoparticles (SLN), nanomicelles, dendrimers, and nanostructured lipid carriers (NLC) have demonstrated markedly enhanced corneal permeation and sustained drug release profiles in preclinical and clinical studies. Advanced platforms including ocular implants, in situ gelling systems, microneedles, and drug-loaded contact lenses represent transformative approaches that minimize dosing frequency while maximizing posterior segment targeting. Mechanisms underpinning controlled release such as mucoadhesion, penetration enhancement, and stimulus-responsive gelation are discussed in the context of glaucoma, posterior segment diseases, and infectious/inflammatory disorders. Despite significant technological advances, challenges related to regulatory compliance, scale-up manufacturing, ocular biocompatibility, and clinical translation continue to limit widespread adoption. This review highlights the critical importance of nanotechnology and advanced drug delivery engineering in reshaping the future landscape of ophthalmic therapeutics.

Keywords: Ocular drug delivery, Ophthalmic nanocarriers, Sustained release, Nanomedicine, Ocular implants, Controlled release

1. Introduction

1.1. Overview of Ocular Drug Delivery

The eye is a highly specialized sensory organ with distinct physiological compartments that pose unique challenges to pharmacological intervention. Ophthalmic drug delivery encompasses strategies to deliver therapeutic agents to the anterior segment (cornea, iris, ciliary body, lens) and the posterior segment (vitreous, retina, choroid). Despite the global burden of ocular diseases—including glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and infectious keratitis—effective drug delivery to ocular tissues remains a persistent unmet need in clinical ophthalmology. [1, 2]

1.2. Anatomical and Physiological Barriers

The eye is protected by multiple formidable barriers that restrict drug penetration and reduce bioavailability (Figure 1). The pre-corneal barrier, constituted by the tear film, rapid nasolachrymal drainage, and blinking reflexes, eliminates over 95% of topically instilled drugs within minutes. [3, 4 [The corneal epithelium, with its tight junctions, acts as a selective membrane limiting paracellular transport, while the blood-aqueous and blood-retinal barriers (BRB) restrict systemic drug delivery to intraocular targets. [5, 6] These barriers collectively necessitate high dosing frequencies and large volumes of conventional formulations, often with limited therapeutic outcomes.

1.3. Need for Improved Ophthalmic Delivery Systems

The therapeutic inadequacies of conventional formulations—primarily driven by poor bioavailability and suboptimal precorneal retention—have catalyzed extensive research into novel drug delivery platforms. [7, 8] Patient non-compliance, arising from the inconvenience of frequent dosing and adverse local reactions, further underscores the urgency of developing sustained-release, patient-friendly drug delivery systems. [9] Advanced formulations employing nanoscale carriers and novel biomaterials are increasingly recognized as pivotal solutions to these challenges. [10]

2. Conventional Ocular Drug Delivery Systems

2.1. Eye Drops, Ointments, and Suspensions

Eye drops remain the most widely prescribed ophthalmic dosage form due to their ease of administration and patient familiarity; however, they achieve less than 5% corneal bioavailability owing to rapid precorneal drainage and the nasolachrymal reflex. [11] Ophthalmic ointments extend contact time but cause blurred vision and are poorly tolerated during waking hours. Suspensions offer a means of delivering insoluble drugs but suffer from non-uniform dosing, particle sedimentation, and ocular irritation. [12] These limitations are summarized in Table 1.

Table 1: Conventional ocular drug delivery systems and their limitations.

Dosage Form	Examples	Advantages	Limitations
Eye drops (solutions)	Timolol, Ciprofloxacin	Easy application, rapid onset	< 5% bioavailability, rapid drainage
Ophthalmic ointments	Erythromycin, Tetracycline	Prolonged contact time	Blurred vision, poor patient compliance
Suspensions	Prednisolone acetate	Insoluble drug delivery	Non-uniform dosing, settling
Gels/Hydrogels	Carbopol-based gels	Improved retention	Limited posterior penetration
Emulsions	Cyclosporine A (Restasis)	Enhanced drug solubilization	Instability, burning sensation

Each system is compared based on application method, representative examples, advantages, and key pharmaceutical limitations.

2.2. Limitations of Conventional Formulations

The fundamental limitation of conventional ocular formulations lies in their inability to sustain therapeutic drug concentrations at the site of action for an adequate duration. [13] Static and dynamic ocular barriers, combined with the small volume of the cul-de-sac (~7 µL), result in rapid drug elimination before meaningful absorption can occur. Furthermore, conventional vehicles provide negligible delivery to posterior segment structures, where vision-threatening pathologies such as AMD and diabetic macular edema predominantly manifest. [4 [[7]

3. Nanotechnology-Based Ocular Drug Delivery

3.1. Polymeric Nanoparticles

Polymeric nanoparticles (PNPs) fabricated from biodegradable materials such as PLGA (poly lactic-co-glycolic acid), chitosan, and albumin have emerged as versatile platforms for sustained ocular drug release. [14 [Their nanoscale dimensions facilitate mucoadhesion to the corneal surface, prolonging precorneal residence and enhancing transcorneal permeation. PLGA-based nanoparticles loaded with cyclosporine A demonstrated sustained drug release over 28 days in animal models of dry eye disease, with significantly improved corneal concentrations compared to conventional eye drops. [14 [[15] Surface modification with polyethylene glycol (PEG) or targeting ligands further enhances cellular uptake and tissue specificity.

3.2. Lipid-Based Nanocarriers

Liposomes, SLNs, and NLCs represent a spectrum of lipid-based drug delivery systems offering excellent biocompatibility and versatility in encapsulating both hydrophilic and lipophilic drugs. [15, 16] Liposomes enhance the corneal uptake of drugs through membrane fusion and endocytosis, and have been clinically applied for cyclosporine A delivery in keratoconjunctivitis sicca. SLNs composed of physiological lipids provide improved physicochemical stability and controlled release, while NLCs—incorporating liquid lipid fractions within a solid matrix—offer greater drug loading capacity and minimize drug expulsion during storage. [16, 19] These systems are summarized alongside other nanotechnology platforms in Table 2.

Table 2: Nanotechnology-based ocular drug delivery systems.

Nanosystem	Drug Examples	Key Features	Notable Studies
Polymeric nanoparticles	Cyclosporine A, PLGA-loaded drugs	Biodegradable, tunable release	Sustained corneal permeation [14 [
Liposomes	Diclofenac, Amphotericin B	Biocompatible, fusogenic	Enhanced precorneal retention [15]
Solid lipid nanoparticles (SLN)	Pilocarpine, Tobramycin	Stable, ocular tolerability	Improved IOP reduction [16]
Nanomicelles	Rapamycin, Voclosporin	High drug loading, small size	Transparent formulation [17]
Dendrimers	Pilocarpine, Brimonidine	Surface modification, mucoadhesion	Enhanced transcorneal transport [18]
Nanostructured lipid carriers	Fluconazole, Dexamethasone	Liquid lipid matrix, flexible	Improved fungal keratitis therapy [19]

Representative nanosystems with drug examples, key features, and notable preclinical/clinical findings

3.3. Nanomicelles and Dendrimers

Nanomicelles—self-assembling amphiphilic copolymer structures with hydrophobic cores—are particularly suited for solubilizing poorly water-soluble ophthalmic drugs such as rapamycin and voclosporin, which target posterior segment inflammation. [17] Their sub-20 nm diameter confers transparency to the formulation, a critical attribute for anterior segment delivery. Dendrimers are highly branched macromolecular scaffolds that enhance mucoadhesion and transcorneal permeation through multiple surface functional groups amenable to drug conjugation or complexation. [18] Polyamidoamine (PAMAM) dendrimers have shown superior corneal permeation of pilocarpine and brimonidine compared to conventional drops in ex vivo and *in vivo* models. [18]

4. Emerging Advanced Ocular Drug Delivery Platforms

4.1. In Situ Gelling Systems

In situ gelling formulations are instilled as low-viscosity solutions that undergo gelation upon contact with the ocular surface in response to physiological stimuli such as pH, temperature, or ionic strength. [20, 27] Poloxamer 407, Carbopol, and gellan gum-based systems have been extensively evaluated and demonstrate markedly prolonged precorneal residence times, thereby reducing dosing frequency for conditions including glaucoma and bacterial keratitis. [20, 27] Timolol maleate formulated in thermosensitive in situ gels achieved comparable intraocular pressure (IOP) reduction to conventional drops with twice-daily rather than four-times-daily dosing schedules in clinical evaluations. [20]

4.2. Ocular Inserts and Implants

Ocular drug-eluting implants represent the most advanced platform for posterior segment sustained delivery. Biodegradable implants such as Ozurdex (dexamethasone intravitreal implant) provide controlled drug release over 3–6 months following a single intravitreal injection, significantly reducing treatment burden in uveitis and macular edema. [24 [Non-biodegradable systems such as Retisert (fluocinolone acetonide) offer multi-year drug delivery via reservoir-diffusion mechanisms, though necessitating surgical implantation. [25] Emerging biodegradable PLGA and PLA rod-shaped and pellet implants are under active investigation for expanding posterior segment indications including geographic atrophy and diabetic retinopathy. These technologies are catalogued in Table 3 (Figure 2).

Table 3: Emerging advanced ocular delivery technologies.

Technology	Drug/Indication	Mechanism	Clinical Status
Ocular implants (biodegradable)	Ozurdex (dexamethasone)	Slow polymer erosion	FDA-approved [24 [
Ocular implants (non-biodegradable)	Retisert (fluocinolone)	Reservoir diffusion	FDA-approved [25]
Microneedles	Bevacizumab, Triamcinolone	Scleral microporation	Preclinical/Phase I [26]
In situ gelling systems	Timolol, Ciprofloxacin	pH/temperature gelation	Clinical use [27]
Contact lens drug delivery	Latanoprost, Antibiotics	Diffusion from polymer matrix	Phase II/III [28]
Nanosuspension drops	Dexamethasone, Loteprednol	Nano-sized particles, enhanced corneal uptake	Marketed [29]

Technologies are listed with representative drugs, delivery mechanism, and current regulatory/clinical status.

4.3. Microneedles and Contact Lens Drug Delivery

Microneedles (MNs) applied to the sclera create micropores enabling direct drug delivery to the suprachoroidal or subretinal space with minimal invasiveness. [26] Hollow and dissolving MN arrays loaded with bevacizumab and triamcinolone are in active preclinical and Phase I development for wet AMD and posterior uveitis, demonstrating pharmacokinetic superiority over conventional intravitreal injection in animal studies. [26] Drug-eluting contact lenses utilize polymer matrices, molecular imprinting, or nanoparticle incorporation to enable continuous anterior segment drug delivery during normal lens wear, making them particularly promising for glaucoma and allergic conjunctivitis management. [28]

5. Mechanisms of Controlled and Sustained Ocular Drug Release

5.1. Controlled Release Mechanisms

Ocular nanocarriers achieve controlled drug release through diffusion from polymer matrices, surface erosion of biodegradable materials, stimulus-responsive phase transitions, and ion-exchange mechanisms. [21] Biodegradable polymers such as PLGA hydrolyze in aqueous ocular media at predictable rates, enabling zero-order or near-zero-order drug release profiles that maintain therapeutic drug levels over days to months. [14 [[21] Encapsulation efficiency, particle size distribution, and polymer molecular
weight are critical parameters governing release kinetics and must be optimized for each therapeutic application.

5.2. Mucoadhesion and Penetration Enhancement

Mucoadhesive polymers such as chitosan, hyaluronic acid, and polyacrylic acid derivatives prolong the interaction of drug-loaded carriers with the mucin layer of the tear film, directly extending precorneal drug residence. [22] Penetration enhancers, including cyclodextrins, bile salts, and tight junction modulators, transiently and reversibly increase paracellular permeability of the corneal epithelium, amplifying drug flux to aqueous humor targets. [23] Efflux pump inhibitors targeting P-glycoprotein at the blood-retinal barrier represent an emerging strategy for improving drug accumulation in posterior ocular tissues following systemic administration. [5, 23]

5.3. Sustained Therapeutic Delivery

Achieving sustained drug release for posterior segment diseases—the most prevalent vision-threatening conditions—requires overcoming the BRB and vitreous humor's diffusion limitations. [6, 24 [Suprachoroidal injection, enabled by purpose-designed microinjectors or microneedles, delivers drug directly to the perichoroidal space, enabling high local bioavailability with minimal systemic exposure. [26] The combination of nanotechnology (nanoparticle carriers) with advanced delivery platforms (implants, microneedles) represents a synergistic strategy for achieving durable therapeutic windows in complex posterior diseases such as AMD and diabetic macular edema. [24 [[26]

6. Therapeutic Applications

6.1. Glaucoma Treatment

Glaucoma, a progressive optic neuropathy driven by elevated IOP, demands lifelong pharmacotherapy with high compliance requirements. Nanoparticle-based formulations of timolol, latanoprost, and bimatoprost have demonstrated sustained IOP-lowering effects in preclinical models, with prolonged therapeutic windows compared to conventional drops. [30, 31] Drug-eluting contact lenses loaded with latanoprost maintained clinically meaningful IOP reduction over 30 days in Phase II trials, representing a paradigm shift in glaucoma management. [28] In situ gelling systems and nanosuspensions further contribute to improved patient compliance and therapeutic consistency in this indication. [20, 30]

6.2. Retinal and Posterior Segment Diseases

AMD, diabetic retinopathy, and retinal vein occlusion collectively represent leading causes of irreversible vision loss globally, with current anti-VEGF therapy requiring frequent intravitreal injections that impose substantial patient and societal burdens. [32, 33] Sustained-release implants and long-acting injectables are actively being developed to extend dosing intervals. The Port Delivery System with ranibizumab (Susvimo) received FDA approval and delivers drug continuously for approximately six months via an indwelling ocular reservoir, exemplifying the clinical translation potential of sustained-release technologies. [33] Nanoparticle-encapsulated nucleic acids and gene therapy vectors are emerging as next-generation platforms for retinal dystrophies. [34 [[35]

6.3. Infectious and Inflammatory Ocular Disorders

Bacterial and fungal keratitis, as well as ocular surface inflammation and uveitis, require effective anterior and posterior drug delivery. Nanoparticle-based antifungal systems employing NLCs and SLNs loaded with fluconazole and amphotericin B have demonstrated markedly superior corneal permeation and mycological cure rates compared to conventional antifungal drops in experimental keratitis. [19, 36] Anti-inflammatory nanocarriers delivering corticosteroids and NSAIDs with reduced systemic absorption are clinically relevant alternatives to systemic immunosuppression in uveitis, minimizing dose-related toxicity. [37, 38]

7. Challenges and Future Perspectives

7.1. Safety, Regulatory, and Manufacturing Challenges

Notwithstanding significant technological advances, the clinical translation of novel ocular drug delivery systems faces substantial hurdles. [39, 40] Safety assessment of novel nanomaterials—including nanotoxicology, immunogenicity evaluation, and long-term biocompatibility profiling—represents a critical regulatory requirement. [41] Regulatory agencies including the FDA and EMA require comprehensive pharmacokinetic and toxicological dossiers for each novel delivery platform and drug combination, significantly extending development timelines and costs. [40, 41] Scale-up manufacturing presents additional challenges: maintaining nanoparticle uniformity, size distribution, and drug loading across industrial-scale production batches remains technically demanding for lipid and polymeric nanosystems. [42] A comparison of modern systems across key delivery parameters is provided in Table 4.

Table 4: Advantages and limitations of modern ocular drug delivery approaches.

System	Drug Penetration	Patient Compliance	Sustained Release	Manufacturing Challenge
Conventional eye drops	Poor (<5%)	High (ease of use)	None	Low
Polymeric nanoparticles	Moderate–High	Moderate	Yes (days–weeks)	Moderate
Liposomes	Moderate	Moderate	Short–Moderate	High (stability)
In situ gels	Moderate	High	Moderate (hours)	Moderate
Ocular implants	High (posterior)	High (long-interval)	Yes (months–years)	High
Microneedles	High (scleral)	Low–Moderate	Yes (controlled)	Very High
Contact lens delivery	Moderate–High	Very High	Moderate (days)	High

Systems compared across drug penetration, patient compliance, sustained release capability, and manufacturing challenges.

7.2. Clinical Translation and Future Directions

The convergence of precision biomaterials, computational drug release modeling, and patient-centric formulation design is accelerating the clinical pipeline of advanced ocular delivery systems. [43, 44 [Theranostic nanoplatforms integrating therapeutic and diagnostic functionalities are emerging, offering the potential for real-time drug release monitoring in ocular tissues. [44 [Gene therapy-enabled delivery using AAV vectors in conjunction with sustained-release biomaterial scaffolds is being evaluated in clinical trials for Leber congenital amaurosis and retinitis pigmentosa. [35, 45] Personalized ocular drug delivery—tailoring formulation design to individual pharmacogenomic profiles and disease severity—represents the next frontier in ophthalmic pharmaceutical care. [43]

8. Conclusion

Advances in ocular drug delivery have been transformative, transitioning the field from suboptimal topical solutions to sophisticated nanotechnology-based and device-integrated platforms that address both anterior and posterior segment therapeutic needs. Polymeric nanoparticles, liposomes, SLNs, nanomicelles, and dendrimers have collectively demonstrated the capacity to enhance corneal bioavailability, prolong drug residence, and enable posterior segment targeting. Emerging platforms—including biodegradable implants, microneedles, in situ gelling systems, and drug-eluting contact lenses—are reshaping patient management paradigms in glaucoma, AMD, diabetic retinopathy, and ocular infections. Overcoming barriers of manufacturing scalability, long-term ocular biocompatibility, and the complex regulatory landscape will be essential for the widespread clinical adoption of these technologies. Future research must prioritize patient-centric design, combination drug strategies, and the integration of gene and cell-based therapies within advanced delivery scaffolds to fully realize the potential of modern ophthalmic pharmaceutical science.

Figures



Fig 1: Barriers and anatomical challenges in ocular drug delivery.



Fig 2: Advanced ocular drug delivery systems and their mechanisms of action.

References

1. Yadav KS, Rajpurohit R, Sharma S. Glaucoma: current treatment and impact of advanced drug delivery systems. Life Sci. 2019;221:362–376.
2. Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev. 2017;122:31–64.
3. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002;28(4):353–369.
4. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131–1135.
5. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21(Suppl 6):S3–S9.
6. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3(2):275–287.
7. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: characterisation and research methods. ScientificWorldJournal. 2014;2014:861904.
8. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47–64.
9. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate–eudragit long-acting nanoparticles: formulation, optimization, *in vitro* and *in vivo* evaluation. AAPS PharmSciTech. 2011;12(4):1087–1101.
10. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348–360.
11. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug Dev Ind Pharm. 2013;39(11):1599–1617.
12. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985;26(4):584–587.
13. Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv. 2016;23(8):3017–3026.
14. Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(5):422–437.
15. Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. J Control Release. 2000;63(1–2):135–140.
16. Bhatt P, Lalani R, Vhora I, Patil S, Bhattacharya C, Misra A. Liposomes encapsulating native and cyclodextrin enclosed tacrolimus: enhanced absorption and biodistribution in ocular therapeutics. Int J Pharm. 2018;534(1–2):39–49.

17. Pepić I, Lovrić J, Filipović-Grčić J. How do polymeric micelles cross epithelial barriers? Eur J Pharm Sci. 2013;50(1):42–55.
18. Spataro G, Malecaze F, Turrin CO, *et al*. Designing dendrimers for ocular drug delivery. Eur J Med Chem. 2010;45(1):326–334.
19. Abdelbary GA, Amin MM, Zakaria MY. Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and *in vivo* studies. Drug Deliv. 2017;24(1):309–319.
20. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine. 2010;6(2):324–333.
21. Langer R. Drug delivery and targeting. Nature. 1998;392(Suppl):5–10.
22. Bhowmick S, Basu SK. Ocular drug delivery: a review. Asian J Pharm. 2018;12(3):S872–S882.
23. Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):106–123.
24. Haller JA, Bandello F, Belfort R Jr, *et al*. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146.
25. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Ophthalmology. 2006;113(6):1020–1027.
26. Jiang J, Gill HS, Ghate D, *et al*. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci. 2007;48(9):4038–4043.
27. Gratieri T, Gelfuso GM, Rocha EM, Sarmento VH, de Freitas O, Lopez RF. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm. 2010;75(2):186–193.
28. Ciolino JB, Stefanescu CF, Ross AE, *et al*. *in vivo* performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials. 2014;35(1):432–439.
29. Addo RT. Ocular drug delivery: recent developments and future challenges. J Pharm Sci. 2015;104(9):2979–3001.
30. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269(1):1–14.
31. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479–1488.
32. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-VEGF antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870.
33. Holekamp NM, Campochiaro PA, Chang MA, *et al*. Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular AMD. Ophthalmology. 2022;129(3):295–307.
34. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog Retin Eye Res. 2010;29(5):376–397.
35. Bennett J, Wellman J, Marshall KA, *et al*. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations. Lancet. 2016;388(10045):661–672.
36. Bhatta RS, Chandasana H, Chhonker YS, *et al*. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: *in vitro* and pharmacokinetic studies. Int J Pharm. 2012;432(1–2):105–112.
37. Nance EA, Woodworth GF, Sailor KA, *et al*. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med. 2012;4(149):149ra119.
38. Liu S, Chang CN, Verma MS, *et al*. Disulfiram-encapsulated hyaluronic acid–modified liposomal nanoparticles for enhanced ocular delivery. Macromol Biosci. 2016;16(12):1836–1851.
39. Delplace V, Payne S, Bhattacharya M. Ocular implants: recent developments in posterior segment drug delivery. Drug Discov Today. 2015;20(12):1498–1505.
40. Shastri DH, Prajapati ST, Patel LD. Thermosensitive ophthalmic in situ hydrogel of moxifloxacin HCl. Curr Drug Deliv. 2010;7(3):238–243.
41. Nance E, Zhang C, Shih TY, Xu Q, Bharat Bhavnani B, Hanes J. Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano. 2014;8(10):10655–10664.
42. Herrero-Vanrell R, Bravo-Osuna I, Andres-Guerrero V, Vicario-de-la-Torre M, Molina-Martinez IT. The potential of using biodegradable microspheres in retinal diseases and other ocular applications. Prog Retin Eye Res. 2014;42:27–43.
43. Bochot A, Fattal E. Liposomes for intravitreal drug delivery: a state of the art. J Control Release. 2012;161(2):628–634.
44. Elnaggar YS. Multifunctional liposomal products for concurrent cancer diagnosis and therapy. Curr Drug Deliv. 2016;13(1):2–19.
45. Russell S, Bennett J, Wellman JA, *et al*. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy. Lancet. 2017;390(10097):849–860.